Introduction: We present a prediction model for progression from early/intermediate to advanced age-related macular degeneration (AMD) within 5.9 years. Objectives: To evaluate the combined role of genetic, nongenetic, and phenotypic risk factors for conversion from early to late AMD over ≥5 years. Methods: Baseline phenotypic characteristics were evaluated based on color fundus photography, spectral-domain optical coherence tomography, and infrared images. Genotyping for 36 single-nucleotide polymorphisms as well as systemic lipid and complement measurements were performed. Multivariable backward logistic regression resulted in a final prediction model. Results and Conclusions: During a mean of 5.9 years of follow-up, 22.4% (n = 52) of the patients (n = 232) showed progression to late AMD. The multivariable prediction model included age, CFH variant rs1061170, pigment abnormalities, drusenoid pigment epithelial detachment (DPED), and hyperreflective foci (HRF). The model showed an area under the curve of 0.969 (95% confidence interval 0.948–0.990) and adequate calibration (Hosmer-Lemeshow test, p = 0.797). In addition to advanced age and carrying a CFH variant, pigment abnormalities, DPED, and HRF are relevant imaging biomarkers for conversion to late AMD. In clinical routine, an intensified monitoring of patients with a high-risk phenotypic profile may be suitable for the early detection of conversion to late AMD.
Objectives: To evaluate the efficacy of faricimab in patients with neovascular age-related macular degeneration (nAMD) that did not respond to other VEGF inhibitors. Methods: This retrospective study included the eyes of patients diagnosed with nAMD who had been switched to faricimab treatment due to the persistence of intraretinal fluid (IRF) and/or subretinal fluid (SRF), despite monthly anti-VEGF treatment with aflibercept, bevacizumab, or ranibizumab using the treat and extend regimen, and who had received at least three faricimab injections following the switch. Best-corrected visual acuity (BCVA) measurement and optical coherence tomography (OCT) analysis were performed at each visit, and the OCT results were graded by two independent readers. Results: We included 41 eyes of 39 patients (21 male, 18 female) with a mean age of 80.5 ± 8.1 years. The median duration of anti-VEGF treatment prior to the switch to faricimab was 5.0 years, with a median of 53 injections. Complete resolution of IRF and SRF was observed after the first dose of faricimab in 12 eyes (29.3%) and after the third dose in 15 eyes (36.6%). Twenty-eight eyes reached a follow-up time after a switch of at least 12 months, with a median of 10 faricimab injections. Of these 28 eyes, 10 eyes (35.7%) exhibited complete IRF/SRF resolution; treatment intervals were extended beyond 4 weeks in 21 eyes (80.7%), and 8 eyes (28.6%) presented complete IRF/SRF resolution under extended treatment intervals at month 12. Central retinal thickness after 12 months was reduced from a median of 368.0 µm to 297.5 µm (p < 0.001), and the BCVA remained stable (p = 0.057). No adverse events were reported throughout the entire treatment period. Conclusions: In nAMD patients with poor anti-VEGF treatment response, complete and fast fluid resolution and the extension of treatment intervals can be reached by switching to faricimab, even after years of prior unsuccessful therapy.
Background: To compare real-life anatomical and functional outcomes of half-dose photodynamic therapy (HD-PDT) and 577 nm subthreshold pulse laser therapy (SPL) in treatment-naïve patients with central serous chorioretinopathy (CSC).Methods: We retrospectively reviewed consecutive treatment-naïve CSC patients with non-resolving subretinal fluid (SRF) for more than 2 months who received either HD-PDT or SPL treatment. One repetition of the same treatment was allowed in patients with persistent SRF after first treatment. Functional and anatomical outcomes were assessed after first treatment and at final visit.Results: We included 95 patients (HD-PDT group, n = 49; SPL group, n = 46). Complete resolution of SRF after a single treatment was observed in 42.9% of HD-PDT-treated patients (n = 21; median time to resolution 7.1 weeks) and in 41.3% of SPL-treated patients (n = 19; median time to resolution 7.0 weeks). In the HD-PDT-group, 44.9% of patients (n = 22) and in the SPL-group, 43.5% (n = 20) of patients, received a second treatment due to persistent SRF, while 12.2% (n = 6) and 15.2% (n = 7), respectively, opted against a second treatment despite persistent SRF. After the final treatment, complete SRF resolution was observed in 61.2% of all HD-PDT-treated patients (n = 30; median time to resolution 8.8 weeks) and 60.9% of all SPL-treated patients (n = 28; median time to resolution 13.7 weeks,p = 0.876). In the final visit, both groups showed significant improvement of BCVA in comparison to baseline (p < 0.001 for all). The change in BCVA from baseline to final visit was similar for the two groups (HD-PDT, median BCVA change 0.10 logMAR (IQR: 0.0-0.2); in SPL group, median BCVA change 0.10 logMAR (IQR: 0.0-0.2),P = 0.344). The CSC subclassification (simple versus complex) had no influence on the anatomical or functional outcome.Conclusions: High-density 577 nm SPL resulted in as good anatomical and functional treatment as HD-PDT and may thus represent a treatment alternative to HD-PDT in CSC.
Age-related macular degeneration (AMD) is a multifactorial retinal disease with a large genetic risk contribution. Reticular pseudodrusen (RPD) is a sub-phenotype of AMD with a high risk of progression to late vision threatening AMD. In a genome-wide association study of 2165 AMD+/RPD+ and 4181 AMD+/RPD- compared to 7639 control participants, both chromosomes 1 (CFH) and 10 (ARMS2/HTRA1) major AMD risk loci are reidentified. However association is only detected for the chromosome 10 locus when comparing AMD+/RPD+ to AMD+/RPD- cases. The chromosome 1 locus is notably absent. The chromosome 10 RPD risk region contains a long non-coding RNA HTRA1-AS1 (ENSG00000285955/BX842242.1) which colocalizes with genetic markers of retinal thickness. HTRA1-AS1 has a strong retinal eQTL signal, pinpointing the parafoveal photoreceptor outer segment layer. Whole genome sequencing of phenotypically extreme RPD cases identifies even stronger enrichment for the chromosome 10 risk genotype.
BACKGROUND: The combination of high inspired oxygen fraction (FiO 2 ) and positive-pressure mask ventilation at induction can lead to atelectasis, increasing the risk of perioperative pulmonary complications. Positive end-expiratory pressure (PEEP) may reduce atelectasis, but prior studies relied on imaging performed before or after induction rather than during ongoing ventilation. We used electrical impedance tomography (EIT) as a bedside, real-time imaging tool. We hypothesized that higher PEEP levels would improve end-expiratory lung aeration and homogenize ventilation distribution without clinically relevant hemodynamic compromise. METHODS: In this prospective, randomized controlled study, 72 adult patients undergoing elective ophthalmic surgery under general anesthesia were enrolled. The effect of three different PEEP levels (0, 5 and 8 mbar) on the distribution of lung ventilation and hemodynamic parameters during mask ventilation at anesthesia induction with 100% (FiO 2 ) were evaluated. Patients were randomized to ascending or descending PEEP sequences to control for order effects. The primary endpoint was the occurrence and the degree of atelectasis represented by the dorsoventral ventilation gradient at each PEEP level as detected by EIT. Secondary endpoints were changes in end-expiratory lung impedance (EELI) (ratio of EELI gain to EELI loss) and changes in lung compliance (ratio of compliance gain to compliance loss) as surrogate markers for atelectasis formation. Hemodynamic parameters were monitored with noninvasive blood pressure, electrocardiography, and electrical cardiometry. RESULTS: EIT was able to show in real-time that higher PEEP levels significantly improved the mean [SD] dorsoventral ventilation gradient (0.48 [0.21] at 0 mbar vs 0.56 [0.28] at 5 mbar vs 0.63 [0.25] at 8 mbar; p<.001), increased the ratio of gain/loss of the end-expiratory lung impedance of the whole lung (3.1 [4.8] at 0 mbar vs 6.1 [8.1] at 5 mbar (~5.1 cmH2O) vs 10.5 [12.2] at 8 mbar (~8.2 cmH2O); p<.001) and increased the compliance gain/loss ratio of the whole lung (2.7 [9.2] at 0 mbar vs 3.8 [10.3] at 5 mbar vs 4.3 [11.3] at 8 mbar; p=.011), independent of the sequence of PEEP (all data dimensionless). Electrical cardiometry revealed that hemodynamic parameters decreased after induction, but these changes were not associated with specific PEEP levels. CONCLUSIONS: Using real-time bedside EIT our study demonstrates that higher PEEP levels during mask ventilation at anesthesia induction can improve ventilation distribution without adverse hemodynamic effects.